Editas Medicine (Nasdaq:EDIT) is a genome editing company which owns the main CRISPR Cas9 patents. It has a market cap of $692.7 million, but makes no profits and pays no dividends. Guest Joseph Busha from JM BUSHA Investment Group and resident expert Paul Theron from Vestact decide whether Editas Medicine is hot or not.
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.